ERBB2 and breast neoplasm: More recently, it has been shown that transmembrane domain targeting peptide antagonizing ErbB2/Neu exhibit anticancer properties by inhibiting breast tumor growth and metastasis in genetically engineered mouse model of breast cancer (Arpel et al., 2014).